Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy May Be Hit With Significant Disgorgement Penalty For GMP Violations

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Ranbaxy's long-running encounter with U.S. FDA over American regulatory allegations of significant deficiencies at two Ranbaxy manufacturing sites - Paonta Sahib and Dewas - may be headed for a settlement in coming months, with the Indian generics flag-bearer paying out several million dollars in penalties

You may also be interested in...



Is Ranbaxy Inching Closer To Resolution Of Its GMP Disputes With U.S. FDA?

MUMBAI - After more than two years of serious deliberations, Ranbaxy seems to be finally moving forward to resolve charges of significant manufacturing lapses leveled by U.S. FDA at two of its India-based sites

Is Ranbaxy Inching Closer To Resolution Of Its GMP Disputes With U.S. FDA?

MUMBAI - After more than two years of serious deliberations, Ranbaxy seems to be finally moving forward to resolve charges of significant manufacturing lapses leveled by U.S. FDA at two of its India-based sites

Ranbaxy Set To launch Aricept Generic In U.S. As FDA OKs Ohm Labs Data; Will Lipitor Be Next ?

MUMBAI - India's largest drug maker Ranbaxy - now part of Japanese pharma Daiichi Sankyo - is set to launch a generic version of the blockbuster Alzheimer's disease drug Aricept (donepezil) in the U.S. market, leading experts to predict that Ranbaxy may also be on track to launch a generic of the world's best selling drug, Lipitor (atorvastatin)

Related Content

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel